This suggests that Wnt pathway inhibitors, including inhibitors of CK1(δ)/ε, can synergize with BTK inhibitors like ibrutinib in patients with CLL or other ROR1+ B-cell malignancies such as MCL. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.